OIG subpoenas United Therapeutics paperwork

Share this article:

The Office of the Inspector General (OIG) of the Department of Health and Human Services is taking a gander at United Therapeutics and its marketing practices. The drugmaker announced Monday that the government agency subpoenaed  “documents regarding...the company's marketing practices relating” to its drugs Remodulin, Tyvaso and Adcirca. All are used to treat pulmonary arterial hypertension (PAH).

The "About Us" section of the OIG's website notes that the HHS Office of the Inspector General is the federal government's largest Office of Inspector General department, and is responsible for sussing out waste, fraud and abuse in HHS programs, which include Medicare and Medicaid, among others.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.